Fernandez-Fresnedo et al, 20094949 Fernandez-Fresnedo G, Segarra A, González E, Alexandru S, Delgado R, Ramos N, et al.; Trabajo de Enfermedades Glomerulares de la Sociedad Española de Nefrología (GLOSEN). Rituximab treatment of adult patients with steroid-resistant focal segmental glomerulosclerosis. Clin J Am Soc Nephrol 2009;4:1317-23.
|
FSGS (SRNS) |
8 |
TAC (3), MMF (7), CyA (2), Csa (7) Steroids (8) |
14.0 ± 4.4 |
1.4 ± 0.5 |
ND |
4 weekly doses of 375mg/m2 (5) 4 weekly doses of 375mg/m2 followed by the same scheme at 12 mo (1) 4 weekly doses of 375mg/m2 followed by the same scheme at 6 mo (1) 8 weekly doses of 375mg/m2 (5) |
12-24 |
PR (1) NR (7) |
2.2 ± 1.8 |
ND |
ND |
Retro |
Kong W.Y. et al, 20135050 Kong WY, Swaminathan R, Irish A. Our experience with rituximab therapy for adult-onset primary glomerulonephritis and review of literature. Int Urol Nephrol 2013;45:795-802.
|
FSGS |
4 |
CyA (2), Csa (2), Aza (1) MMF (1), steroids (3) |
ND |
ND |
12 relapses (1) 0 relapses (3) |
375mg/m2, single dose |
11-51 |
CR (2), PR (1), NR (1) |
ND |
1 relapses (1) 0 relapses (3) |
Steroids(2) |
Retro |
Ochi A. et al. 20125151 Ochi A, Takei T, Nakayama K, Iwasaki C, Kamei D, Tsuruta Y, et al. Rituximab treatment for adult patients with focal segmental glomerulosclerosis. Intern Med 2012;51:759-62.
|
FSGS (2SRNS, 2SDNS) |
4 |
Csa (2), MZ (1), CyA (1), MMF (1), steroids (4), |
3.6-13.0 |
0.5-2.1 |
2 patients relapses more than 3 times |
375mg/m2, single dose |
variable |
CR(2) NR (2) |
DN |
2 patients relapse |
Steroids (2) |
Retro |
Rocatello D. et al, 20175252 Roccatello D, Sciascia S, Rossi D, Alpa M, Naretto C, Radin M, et al. High-Dose Rituximab Ineffective for Focal Segmental Glomerulosclerosis: A Long-Term Observation Study. Am J Nephrol 2017;46:108-13.
|
FSGS |
8 |
Supportive treatment |
5.3 ± 1.9 |
2.6 ± 1.2 |
NA |
8 weekly doses of 375mg/m2
|
29.1 ± 8.8 |
NR (7) PR (1) |
3.5 ± 2.5 |
ND |
Only supportive treatment |
Prosp |
Munyentwali et al, 20135656 Munyentwali H, Bouachi K, Audard V, Remy P, Lang P, Mojaat R, et al. Rituximab is an efficient and safe treatment in adults with steroid-dependent minimal change disease. Kidney Int 2013;83:511-6.
|
MCD steroid-dependent (15); MCD steroid-resistant (2) |
17 |
TAC(2), MMF (12), Csa (13), CyA (4), LEV (7) mechlorethamina (3), chlorambucil (1), pefloxacin (1), basiliximab (1), steroids (17) |
0.05-6.2 |
ND |
All patients had at least 2 relapses |
375mg/m2, single dose (1) 2 weekly doses of 375mg/m2 (7) 3 weekly doses of 375mg/m2 (4) 4 weekly doses 375mg/m2 (3) 1000mg on day 1 and 15 (2) |
5.1-82.2 |
CR (15), NR (2) |
NA |
6 patients with at least 1 relapse each |
CyA (1); Steroids (4); TAC (1) |
Retro |
Takei T. et al, 20135757 Takei T, Itabashi M, Moriyama T, Kojima C, Shiohira S, Shimizu A, et al. Effect of single-dose rituximab on steroid-dependent minimal-change nephrotic syndrome in adults. Nephrol Dial Transplant 2013;28:1225-32.
|
MCD steroid-dependent and frequently relapse |
25 |
MMF (3), CyA (20), MZ (5), steroids (25) |
2.5 ± 3.5 |
0.7 ± 0.2 |
62 relapses (patients experienced at least 1) |
Single dose of 375mg/m2,6 months apart, during 1 year (25) |
12 |
CR (25) |
0.6 ± 0.1 |
4 patients with 1 relapse each |
CyA (6), steroids (4) |
Prosp |
Iwabuchi Y. et al, 20145858 Iwabuchi Y, Takei T, Moriyama T, Itabashi M, Nitta K. Long-term prognosis of adult patients with steroid-dependent minimal change nephrotic syndrome following rituximab treatment. Medicine (Baltimore) 2014;93:e300.
|
MCD steroid-dependent and frequently relapse |
25 |
MMF(1), CyA(20), MZ(6), TAC(1)steroids (28) |
2.5 ± 4.9 |
0.7 ± 0.2 |
108 relapses (patients experienced at least 1) |
Single dose of 375mg/m2, 6 months apart, during 2 years |
24 |
CR (25) |
0.7 ± 0.1 |
8 patients with 1 relapse each |
CyA (5), Steroids (4) |
Prosp |
Papakrivopoulou E. et al, 20165959 Papakrivopoulou E, Shendi AM, Salama AD, Khosravi M, Connolly JO, Trompeter R. Effective treatment with rituximab for the maintenance of remission in frequently relapsing minimal change disease. Nephrology (Carlton) 2016;21:893-900.
|
MCD steroid-dependent and frequently relapse |
15 |
MMF(3), CyA(5), LEV (3),Csa (6), TAC (4) |
ND |
0.95 ± 0.3 |
39 relapses (patients experienced at least 1) |
Single dose of 375mg/m2, 6 months apart, during 1 year (15) |
43 |
ND |
ND |
7 patients with 1 relapse each |
Dose reduction of TAC and Csa; steroids (0) |
Prosp |
Fenoglio R. et al, 20186060 Fenoglio R, Sciascia S, Beltrame G, Mesiano P, Ferro M, Quattrocchio G, et al. Rituximab as a front-line therapy for adult-onset minimal change disease with nephrotic syndrome. Oncotarget 2018;9:28799-804.
|
MCD |
6 |
RTX as first line therapy |
11.75 ± 7.8 |
1.95 ± 1.5 |
NA |
4 weekly doses of 375mg/m2
|
8-36 months |
CR (5) |
0.86 ± 0.18 |
0 relapses |
None |
Case series |